Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Kumps, Candy ^a   Fieuw, Annelies ^a   Mestdagh, Pieter ^a   Menten, Björn ^a   Lefever, Steve ^a   Pattyn, Filip ^a   de Brouwer, Sara ^a   Sante, Tom ^a   Schulte, Johannes Hubertus ^b   Schramm, Alexander ^b   van Roy, Nadine ^a   van Maerken, Tom ^a   Noguera, Rosa ^c   Combaret, Valérie ^d   Devalck, Christine ^e   Westermann, Frank ^f   Laureys, Geneviève ^a   Eggert, Angelika ^b   Vandesompele, Jo ^a   de Preter, Katleen ^a   Speleman, Frank ^a   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF VALENCIA   (Spain)

^d CENTRE LÉON BÉRARD   (France)

^e HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 17; MICRORNA 19B; REGULATOR PROTEIN; RGS5 PROTEIN; RING FINGER PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; GENE ACTIVATION; GENE CLUSTER; GENE DELETION; GENE LOSS; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC GAIN; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE; REGULATOR GENE; RNF11 GENE; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOZYGOTE; HUMANS; MICRORNAS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RGS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84871861658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052321     Document Type: Article

References (78)

1. Maris JM, (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202-2211.
2. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, et al. (2007) ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46: 1098-1108.
3. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, et al. (2005) Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23: 2280-2299.
4. Brodeur GM, (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
5. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature.
6. Chen Y, Takita J, Choi YL, Kato M, Ohira M, et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
7. George RE, Sanda T, Hanna M, Frohling S, Luther W Jr, et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978.
8. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970.
9. Caren H, Abel F, Kogner P, Martinsson T, (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416: 153-159.
10. Holzel M, Huang S, Koster J, Ora I, Lakeman A, et al. (2010) NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142: 218-229.
11. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589-593.
12. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, et al. (2010) The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 40: 762-773.
13. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, et al. (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
14. Manzur M, Ganss R, (2009) Regulator of G protein signaling 5: a new player in vascular remodeling. Trends Cardiovasc Med 19: 26-30.
15. Gantier MP, Stunden HJ, McCoy CE, Behlke MA, Wang D, et al. (2012) A miR-19 regulon that controls NF-kappaB signaling. Nucleic Acids Res.
16. Azmi PB, Seth AK, (2009) The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling. Anticancer Res 29: 2253-2263.
17. Azmi P, Seth A, (2005) RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation. Eur J Cancer 41: 2549-2560.
18. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, et al. (2010) MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 29: 1394-1404.
19. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, et al. (2008) MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 122: 699-704.
20. Yang HW, Chen YZ, Takita J, Soeda E, Piao HY, et al. (2001) Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deleted in neuroblastoma at chromosome 1p36.2. Oncogene 20: 5075-5083.
21. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, et al. (2008) High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9: 353.
22. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, et al. (2006) High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66: 3673-3680.
23. Slack A, Lozano G, Shohet JM, (2005) MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 228: 21-27.
24. Huang da W, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
25. Mac SM, D'Cunha CA, Farnham PJ, (2000) Direct recruitment of N-myc to target gene promoters. Mol Carcinog 29: 76-86.
26. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, et al. (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
27. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, et al. (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13: 803-812.
28. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, et al. (2008) ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68: 9735-9745.
29. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, et al. (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256.
30. De Brouwer S, Mestdagh P, Lambertz I, Pattyn F, De Paepe A, et al. (2011) Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. Int J Cancer.
31. Loven J, Zinin N, Wahlstrom T, Muller I, Brodin P, et al. (2010) MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci U S A 107: 1553-1558.
32. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, et al. (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 70: 1377-1388.
33. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM, (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995.
34. Chesler L, Weiss WA, (2011) Genetically engineered murine models- Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol 21: 245-255.
35. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, et al. (2012) Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21: 362-373.
36. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, et al. (2012) Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. Sci Transl Med 4: 141ra191.
37. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, et al. (2012) The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. Cancer Cell 22: 117-130.
38. Azarova AM, Gautam G, George RE, (2011) Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 21: 267-275.
39. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, et al. (2010) Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16: 4353-4362.
40. Schonherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, et al. (2012) Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene.
41. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, et al. (2009) The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69: 3249-3255.
42. Huang G, Song H, Wang R, Han X, Chen L, (2012) The relationship between RGS5 expression and cancer differentiation and metastasis in non-small cell lung cancer. J Surg Oncol 105: 420-424.
43. Berger M, Bergers G, Arnold B, Hammerling GJ, Ganss R, (2005) Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood 105: 1094-1101.
44. Connor MK, Seth A, (2004) A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interactions with E2s and E3s. Oncogene 23: 2089-2095.
45. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, et al. (2010) Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 16: 2971-2978.
46. Meyle KD, Guldberg P, (2009) Genetic risk factors for melanoma. Hum Genet 126: 499-510.
47. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, et al. (2008) Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 68: 2599-2609.
48. Toledo F, Wahl GM, (2007) MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39: 1476-1482.
49. Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, et al. (2006) Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66: 9646-9655.
50. Palmer RH, Vernersson E, Grabbe C, Hallberg B, (2009) Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420: 345-361.
51. Kim M, Yim SH, Cho NS, Kang SH, Ko DH, et al. (2009) Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet Cytogenet 195: 59-65.
52. Li J, Poi MJ, Tsai MD, (2011) Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry 50: 5566-5582.
53. Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, et al. (2012) Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer 11: 6.
54. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, et al. (2009) The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 106: 9435-9440.
55. Gogada R, Amadori M, Zhang H, Jones A, Verone A, et al. (2011) Curcumin induces Apaf-1-dependent, p21-mediated caspase activation and apoptosis. Cell Cycle 10: 4128-4137.
56. Hofer-Warbinek R, Schmid JA, Mayer H, Winsauer G, Orel L, et al. (2004) A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53. Cell Death Differ 11: 1317-1325.
57. Chiang MF, Yeh ST, Liao HF, Chang NS, Chen YJ, (2012) Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed Pharmacother 66: 433-438.
58. Hu BS, Tan JW, Zhu GH, Wang DF, Zhou X, et al. (2012) WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721. World J Gastroenterol 18: 3020-3026.
59. Menges CW, Altomare DA, Testa JR, (2009) FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle 8: 2528-2534.
60. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, et al. (2012) Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. Cancer Cell 22: 359-372.
61. Tzoneva G, Ferrando AA, (2012) Recent Advances on NOTCH Signaling in T-ALL. Curr Top Microbiol Immunol 360: 163-182.
62. Reiff T, Huber L, Kramer M, Delattre O, Janoueix-Lerosey I, et al. (2011) Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development 138: 4699-4708.
63. Gustafson WC, Weiss WA, (2010) Myc proteins as therapeutic targets. Oncogene 29: 1249-1259.
64. Hogarty MD, Maris JM, (2012) PI3King on MYCN to improve neuroblastoma therapeutics. Cancer Cell 21: 145-147.
65. Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, et al. (2011) Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147: 1066-1079.
66. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, et al. (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6: e18064.
67. Molenaar JJ, Domingo-Fernandez R, Ebus ME, Lindner S, Koster J, et al. (2012) LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet.
68. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
69. Van Maerken T, Vermeulen J, Hoebeeck J, Mestdagh P, De Wilde B, et al. (2012) Discovering hidden Significance in Neuroblastoma Gene Expression Studies using the Neuroblastoma Gene Server. BMC Research Notes (submitted).
70. Menten B, Pattyn F, De Preter K, Robbrecht P, Michels E, et al. (2005) arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics 6: 124.
71. van de Wiel MA, Brosens R, Eilers PH, Kumps C, Meijer GA, et al. (2009) Smoothing waves in array CGH tumor profiles. Bioinformatics 25: 1099-1104.
72. Olshen AB, Venkatraman ES, Lucito R, Wigler M, (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572.
73. Smedley D, Haider S, Ballester B, Holland R, London D, et al. (2009) BioMart-biological queries made easy. BMC Genomics 10: 22.
74. Lefever S, Vandesompele J, Speleman F, Pattyn F, (2009) RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res 37: D942-945.
75. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J, (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19.
76. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, et al. (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10: R64.
77. Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, et al. (2008) High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 36: e143.
78. Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, et al. (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15: 541-555.